Taylor Wessing advises Fovea Pharmaceuticals on its €30m second financing round
02-Jan-2008 | Corporate, Intellectual Property
CLIENT
Fovea Pharmaceuticals SA
VALUE
€30 million
TRANSACTION
Series B financing
DESCRIPTION
Fovea Pharmaceuticals SA, a biomedical and technological company specialising in the development of innovative drug therapy for the treatment of ophthalmic diseases, has just concluded its second financing round « series B » for a total amount of €30 million, to be paid in two lots in the form of shares with equity warrants.